Day: September 1, 2020

PARIS – Le 1 septembre 2020 – Sanofi annonce aujourd’hui que l’essai international de phase III évaluant Kevzara® (sarilumab) administré par voie intraveineuse à une dose de 200 mg ou de 400 mg[a] à des patients hospitalisés pour une forme sévère ou critique[b] de COVID-19 n’a pas atteint son critère d’évaluation principal ni secondaire[c], comparativement au placebo et, dans les deux cas, en plus des soins hospitaliers habituels. Cet essai randomisé a inclus 420 patients et a été mené en dehors des États-Unis, à savoir en Argentine, au Brésil, au Canada, au Chili, en France, en Allemagne, en Israël, en Italie, au Japon, en Russie et en Espagne (86 patients dans le groupe placebo, 161 dans le groupe 200 mg, et 173 dans le groupe 400 mg).« Bien que cet essai n’ait pas donné les résultats que nous espérions, nous sommes fiers du travail...

Steinhausen, September 1, 2020 – Schweiter Technologies is strengthening its US display business and has signed and closed an agreement to acquire the foam board business of Newell Brands Inc. (‘Newell’). In 2019, the acquired business generated sales of around USD 39 million. The purchase price is in the middle single-digit million USD range.The acquired assets include the production site and assets in Statesville, NC. Similar manufacturing methods, logistics networks, and sales channels will provide for seamless business integration.The business is currently depressed by Covid-19 and will undergo some restructuring.For further information please contact:Martin Klöti, CFOTel. +41 41 757 77 00, Fax +41 41 757 70 01, martin.kloeti@schweiter.comPlease find the Media release in the PDF attached:Media release (PDF).pdf

Steinhausen, 1. September 2020 – Schweiter Technologies verstärkt sein Display-Geschäft in den USA und hat eine Vereinbarung zum Erwerb des Foamboard-Geschäfts von Newell Brands Inc. („Newell“) unterzeichnet und abgeschlossen. Im Jahr 2019 erzielte das erworbene Geschäft einen Umsatz von rund 39 Mio. USD. Der Kaufpreis liegt im mittleren einstelligen Millionen USD-Bereich.Die übernommenen Vermögenswerte umfassen den Produktionsstandort, die Produktionsanlagen und weitere Vermögenswerte in Statesville, NC. Ähnliche Herstellungsmethoden, Logistiknetzwerke und Vertriebskanäle werden für eine nahtlose Integration des erworbenen Geschäftsbereiches sorgen.Das Geschäft ist momentan negativ von den Covid-19 Auswirkungen betroffen und wird restrukturiert werden.Für weitere Informationen:Martin Klöti, CFOTel. +41 41 757 77 00, Fax +41 41 757 70...

PERTH, Western Australia, Aug. 31, 2020 (GLOBE NEWSWIRE) — Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) wishes to advise that Ms Elissa Brown has resigned from her role as Chief Financial Officer (CFO) of Perseus with effect from October 31, 2020.Elissa is one of Perseus’s longest serving employees having joined the Company in 2010 as Financial Controller before being promoted to the role of CFO in February 2013.  During her time with Perseus, Elissa has been a key member of our senior management team that has worked tirelessly to successfully transition Perseus from a junior explorer into a multi-mine multi-jurisdictional gold company. Going forward, Ms Lee-Anne de Bruin has agreed to join Perseus as CFO, replacing Elissa.  Lee-Anne has an impressive history in senior finance roles in the resources...

This news release should be read in conjunction with Amarillo Gold Corporation’s condensed interim consolidated financial statements and management’s discussion and analysis for the six months ended June 30, 2020. Both are available at www.amarillogold.com and filed under the Company’s profile on SEDAR at www.sedar.com.All monetary amounts are expressed in Canadian dollars unless otherwise specified.TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) — Amarillo Gold Corporation (Amarillo or the Company) (TSXV: AGC, OTCQB: AGCBF) today announced its financial results for the six months ended June 30, 2020.Amarillo achieved several key corporate milestones in the second quarter of 2020.Completed the positive definitive feasibility study for the Posse Gold ProjectIt supports an open pit mine and carbon-in-leach operation with dry stack tailings...

DUBLIN, Ireland and CHICAGO, Aug. 31, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the subscription period of its previously announced rights offering expired at 5:00 p.m., New York City time, on August 31, 2020. As previously disclosed, the Company had agreed to undertake the rights offering in connection with the Company’s January 2020 private placement of units consisting of 6.500% Exchangeable Senior Subordinated Notes due 2025 and Limited Recourse Royalty-Linked Subordinated Notes.Pursuant to the rights offering, the Company and Iterum Therapeutics Bermuda Limited, the...